ENTRY       D11811                      Drug
NAME        Tofersen (JAN/USAN/INN);
            BIIB067;
            Qalsody (TN)
PRODUCT     QALSODY (Biogen)
FORMULA     C230H317N72O123P19S15
EXACT_MASS  7123.1589
MOL_WEIGHT  7127.8631
SEQUENCE    caggatacat ttctacagcu
  TYPE      Nucleotide
REMARK      Product: D11811<US>
EFFICACY    Translation inhibitor
  DISEASE   Amyotrophic lateral sclerosis (SOD1 mutated) [DS:H00058]
  TYPE      Antisense oligonucleotide
COMMENT     Treatment of amyotrophic lateral sclerosis
TARGET      SOD1* [HSA_VAR:6647v1] [HSA:6647] [KO:K04565] (mRNA)
  PATHWAY   hsa04146(6647)  Peroxisome
            hsa04213(6647)  Longevity regulating pathway - multiple species
            hsa05014(6647)  Amyotrophic lateral sclerosis
            hsa05022(6647)  Pathways of neurodegeneration - multiple diseases
BRITE       USP drug classification [BR:br08302]
             Central Nervous System Agents
              Amyotrophic Lateral Sclerosis (ALS) Agents
               Tofersen
                D11811  Tofersen (JAN/USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Oxidoreductases (EC1)
               Superoxide dismutase
                SOD1* [HSA_VAR:6647v1]
                 D11811  Tofersen (JAN/USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11811
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11811
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D11811
DBLINKS     CAS: 2088232-70-4
            PubChem: 405226676
///
